skip to Main Content
Expert in Metabolic Dysfunction-associated Steatohepatitis

Explore our industry-leading
translational models of
NASH/MASH & HCC

  • Upcoming event : AASLD The Liver Meeting
  • November 10-14, 2023

Gubra’s flagship model GAN DIO-MASH is top-ranked by LITMUS consortium for its human proximity score and clinical translatability. Explore our model portfolio and latest findings to ensure a successful preclinical study.

AASLD – The Liver Meeting

Download our posters


Meet Gubra at the AASLD – The Liver Meeting! Gubra is presenting 5 posters to discuss the clinical translatability of our flagship GAN DIO-MASH model, as well as other biopsy-confirmed preclinical models. Download the posters to learn more.

Standard Study Outlines

We are experts in bridging preclinical and clinical development.


MICHAEL FEIGH
Vice President, Scientific Sales

Michael’s primary focus is on MASH (NASH), MASH-HCC (NASH-HCC), IPF and IBD. Michael provides customers with scientific expertise in metabolic and fibrotic diseases, and knowhow for the preclinical evaluation of drug candidates from discovery to IND-enabling.

Let’s meet at the EASL 2023

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top